减重手术中标准化三剂静脉氨甲环酸方案的可行性:一项预试验
这项前瞻性序贯周期预试验纳入1077例接受袖状胃切除、Roux-en-Y胃旁路或修正手术的患者,在交替的3个月TXA与非TXA周期中评估标准化三剂静脉TXA方案的可行性。招募率96.0%,方案依从性94.5%,30天结局 ascertainment 100.0%;临床显著出血在TXA周期为1.46%、非TXA周期为2.84%(p=0.174),无30天血栓栓塞事件。
要点
- 标准化三剂静脉TXA方案在减重手术日常实践中可行,依从性高。
- TXA周期临床显著出血1.46% vs 非TXA周期2.84%,差异无统计学意义。
- 吻合类手术出血 odds 高于袖状胃切除(OR 5.41),未见治疗与术式交互作用。
核心结论
- 标准化三剂静脉TXA方案在常规减重手术实践中可行,依从性高且30天结局 ascertainment 完整。
- 鉴于本预试验出血事件率低,需足够把握度的研究确定TXA是否真正减少术后出血及效果是否因术式而异。
研究设计与样本
- 前瞻性、序贯周期预试验,纳入1077例接受袖状胃切除、Roux-en-Y胃旁路或修正手术的患者。
- 在交替的3个月TXA与非TXA周期中实施标准化三剂静脉TXA方案,主要结局为可行性。
主要发现
- 筛查1122例,入组1077例(96.0%;95% CI 94.7-97.1%)。
- 总体依从周期分配治疗为94.5%(95% CI 93.0-95.8%),所有启动TXA者完成三剂方案,30天结局 ascertainment 为100.0%(95% CI 99.7-100.0%)。
- 临床显著出血在TXA周期为1.46%、非TXA周期为2.84%(p=0.174)。
- ITT分析中TXA分配与袖状胃切除患者出血无显著关联(OR 0.55;95% CI 0.10-2.53;p=0.449),吻合类手术出血 odds 高于袖状胃切除(OR 5.41;95% CI 1.86-18.64;p=0.002)。
- 未发现治疗与术式交互作用(p=0.985),两组手术时间与住院时长相似,无30天血栓栓塞事件。
临床怎么用
- 该方案可作为减重手术围术期TXA标准化给药的可行性参考,但疗效证据尚不足以支持常规推广。
- 吻合类手术出血风险较高,TXA的术式特异性效果仍需进一步研究。
局限性
- 为预试验,出血事件率低,未针对出血终点做把握度计算。
- 采用序贯周期设计而非个体随机,可能存在时间相关混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tranexamic acid (TXA) has been increasingly evaluated in bariatric surgery; however, heterogeneity remains in dosing and timing, and the feasibility of implementing a standardized multidose regimen in routine practice is not well established. This pilot study evaluated implementation of a standardized three-dose intravenous TXA protocol in metabolic bariatric surgery. METHODS: This prospective, sequential-period pilot study included 1077 patients undergoing sleeve gastrectomy (SG), Roux-en-Y gastric bypass, or revisional surgery during alternating 3-month TXA and non-TXA periods. The primary outcome was feasibility, assessed by recruitment, protocol adherence, and completeness of 30-day outcome ascertainment. Postoperative bleeding, operative time (OT), length of stay (LOS), and thromboembolic events were evaluated exploratorily. Bleeding was assessed using Firth penalized logistic regression under intention-to-treat (ITT) and as-treated frameworks. RESULTS: Of 1,122 patients screened, 1077 were enrolled (96.0%; 95% CI 94.7-97.1%). Overall adherence to period-assigned treatment was 94.5% (95% CI 93.0-95.8%); all patients initiating TXA completed the three-dose regimen, and 30-day outcome ascertainment was 100.0% (95% CI 99.7-100.0%). Clinically significant bleeding occurred in 1.46% of patients assigned to TXA periods vs. 2.84% assigned to non-TXA periods (p = 0.174). In ITT analysis, TXA allocation was not significantly associated with bleeding among SG patients (OR 0.55; 95% CI 0.10-2.53; p = 0.449), whereas anastomotic procedures had higher bleeding odds than SG (OR 5.41; 95% CI 1.86-18.64; p = 0.002). No treatment-by-procedure interaction was identified (p = 0.985). OT and LOS were similar between groups, and no 30-day thromboembolic events occurred. CONCLUSION: Implementation of a standardized three-dose intravenous TXA protocol was feasible within routine bariatric surgical practice, with high adherence and complete outcome ascertainment. Given the low bleeding event rate observed in this pilot, adequately powered studies are needed to determine whether TXA meaningfully reduces postoperative bleeding and whether its effect differs by procedure type.
引用
- Llamuca-Castro P, Lima D, Estrada A, et al. Feasibility of a standardized three-dose intravenous tranexamic acid protocol in bariatric surgery: a pilot study. Surg Endosc. 2026. PMID: 42844371. doi:10.1007/s00464-026-13494-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。